These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 20021022)

  • 1. LHRH-PE40-Induced Vascular Leak Syndrome.
    Li J; Zhang JK
    Toxicol Mech Methods; 2006; 16(8):473-6. PubMed ID: 20021022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A recombinant protein LHRH-PE40 for tumour therapy: preclinical safety studies.
    Li J; Sun Y; Zhang J
    Basic Clin Pharmacol Toxicol; 2006 Dec; 99(6):398-404. PubMed ID: 17169119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological hormone atrophy by gonadotropin-based drug.
    Li J; Zhang J
    Int J Exp Pathol; 2006 Dec; 87(6):495-9. PubMed ID: 17222217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single molecular recognition force spectroscopy study of a luteinizing hormone-releasing hormone analogue as a carcinoma target drug.
    Zhang J; Wu G; Song C; Li Y; Qiao H; Zhu P; Hinterdorfer P; Zhang B; Tang J
    J Phys Chem B; 2012 Nov; 116(45):13331-7. PubMed ID: 23094688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retracted: Combined therapy using LHRH-PE40 and anti-CD40 dendritic cells substantially eliminate tumor cells.
    Zhang L; Du T; Ma D; Guo F; Li Z; Yan H
    J Cell Biochem; 2019 May; 120(5):8093-8100. PubMed ID: 30485508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.
    Posey JA; Khazaeli MB; Bookman MA; Nowrouzi A; Grizzle WE; Thornton J; Carey DE; Lorenz JM; Sing AP; Siegall CB; LoBuglio AF; Saleh MN
    Clin Cancer Res; 2002 Oct; 8(10):3092-9. PubMed ID: 12374676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Construction, expression and refolding of recombinant luteinizing hormone releasing hormone-angiogenin toxin].
    Ni ZL; Zhang QH; Qu QY; Lü HL; Fan SY; Cai C
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Aug; 45(8):680-4. PubMed ID: 21055247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifertility effects of luteinizing hormone-releasing hormone (LHRH) agonists.
    Labrie F; Bélanger A; Kelly PA; Séguin C; Cusan L; Lefebvre FA; Reeves JJ; Lemay A; Faure N; Gourdeau Y; Raynaud JP
    Prog Clin Biol Res; 1981; 74():273-91. PubMed ID: 6275404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The Prediction of the Molecular Biology Characteristics of Recombinant Fusion Exotoxin B7-1-Linker-PE40 and B7-2-Linker-PE40].
    Zhang HL; Xi YZ; Kong FH; Chen RG; Yuan ZH; Liu N; Guan HR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2001 Dec; 9(4):327-332. PubMed ID: 12578573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of high-affinity interleukin 4 receptors on murine sarcoma cells and receptor-mediated cytotoxicity of tumor cells to chimeric protein between interleukin 4 and Pseudomonas exotoxin.
    Puri RK; Ogata M; Leland P; Feldman GM; FitzGerald D; Pastan I
    Cancer Res; 1991 Jun; 51(11):3011-7. PubMed ID: 2032239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of dichotomous action of IL-2-Pseudomonas exotoxin 40 (IL-2-PE40) on cell-mediated and humoral immune response.
    Volk HD; Müller S; Yarkoni S; Diamantstein T; Lorberboum-Galski H
    J Immunol; 1994 Sep; 153(6):2497-505. PubMed ID: 8077661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome.
    Damle NK; Doyle LV
    J Immunol; 1989 Apr; 142(8):2660-9. PubMed ID: 2522965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal microSPECt/CT imaging and pharmacokinetics of synthetic luteinizing hormone-releasing hormone (LHRH) vaccine in rats.
    Chang CH; Hsu WC; Wang CY; Jan ML; Tsai TH; Lee TW; Lynn SG; Yeh CH; Chang TJ
    Anticancer Res; 2007; 27(5A):3251-8. PubMed ID: 17970068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histamine improves survival and protects against interleukin-2-induced pulmonary vascular leak syndrome in mice.
    Hornyak SC; Orentas DM; Karavodin LM; Gehlsen KR
    Vascul Pharmacol; 2005 Mar; 42(4):187-93. PubMed ID: 15820445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system.
    Günthert AR; Gründker C; Bongertz T; Nagy A; Schally AV; Emons G
    Breast Cancer Res Treat; 2004 Oct; 87(3):255-64. PubMed ID: 15528968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40).
    Pai LH; Gallo MG; FitzGerald DJ; Pastan I
    Cancer Res; 1991 Jun; 51(11):2808-12. PubMed ID: 2032221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic luteinizing hormone releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to prostate cancer immunotherapy.
    Finstad CL; Wang CY; Kowalski J; Zhang M; Li ML; Li XM; Xia WG; Bosland MC; Murthy KK; Walfield AM; Koff WC; Zamb TJ
    Vaccine; 2004 Mar; 22(9-10):1300-13. PubMed ID: 15003660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein.
    Arteaga CL; Hurd SD; Dugger TC; Winnier AR; Robertson JB
    Cancer Res; 1994 Sep; 54(17):4703-9. PubMed ID: 8062268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medial preoptic microimplants of the antiestrogen, keoxifene, affect luteinizing hormone-releasing hormone mRNA levels, median eminence luteinizing hormone-releasing hormone concentrations and luteinizing hormone release in ovariectomized, estrogen-treated rats.
    Petersen SL; Cheuk C; Hartman RD; Barraclough CA
    J Neuroendocrinol; 1989 Aug; 1(4):279-83. PubMed ID: 19210441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model.
    Sokolova EA; Shilova ON; Kiseleva DV; Schulga AA; Balalaeva IV; Deyev SM
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.